Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
PTC Therapeutics’ Translarna for nmDMD is Conditionally Approved in European Union
Recent Posts
- From clothing to handwriting, I’m still adapting to ALS and cultural change
- Better cardiovascular health linked to lower ALS risk in large study
- Common viral infections may lead to faster ALS progression, study suggests
- ALS community mourns Brooke Eby, who shared her journey with millions
- MDA Engage: ‘I am not alone’ was the biggest takeaway in Chicago